Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system
- PMID: 1998989
- DOI: 10.1007/BF00685119
Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system
Abstract
A flow-through system was used to study the cellular pharmacokinetics of 5-fluorouracil (5-FU) in four human cell lines (squamous-cell carcinoma HEp-2, colon carcinoma WiDr, hepatoma Hep G2, and breast carcinoma MCF-7) as well as in the rat hepatoma H35 cell line and in freshly isolated rat hepatocytes. The system made it possible to restrict the decrease in the concentration of 5-FU in the medium, to keep the volume in which the metabolites accumulated relatively small, and to study the dynamics of a response during and after a change in the composition of the eluent. Clearance of 5-FU from the eluent was achieved predominantly (greater than 95%) by its catabolism to dihydrofluorouracil in the tumor cell lines and to 2-fluoro-beta-alanine in the hepatocytes. Not only rat hepatocytes but also HEp-2 cells showed relatively high clearance values. A concentration-dependent 5-FU elimination was observed, indicating saturation of 5-FU elimination according to Michaelis-Menten kinetics (Km 14-22 microM). The maximal velocity (Vmax) values ranged from 0.025 to 0.13 nmol 5-FU/10(6) cells per minute. For HEp-2 cells, high-concentration pulse injections of 5-FU, thymine, uridine, or uracil immediately led to a reduction in 5-FU conversion, followed by recovery within 5 min. The flow-through system proved to be adequate for the study of the non-linear pharmacokinetics of 5-FU in different intact cells and for the comparison of various manipulations of these pharmacokinetics.
Similar articles
-
Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation.Cancer Res. 1985 Jan;45(1):116-21. Cancer Res. 1985. PMID: 3965128
-
Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase.Cancer Res. 1985 Nov;45(11 Pt 1):5553-6. Cancer Res. 1985. PMID: 4053028
-
Clinical pharmacokinetics of fluorouracil and folinic acid.Semin Oncol. 1992 Apr;19(2 Suppl 3):82-92. Semin Oncol. 1992. PMID: 1557660 Review.
-
Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver.Cancer Res. 1987 Oct 15;47(20):5261-5. Cancer Res. 1987. PMID: 3652033
-
Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.Pharmacogenomics. 2013 May;14(7):799-811. doi: 10.2217/pgs.13.54. Pharmacogenomics. 2013. PMID: 23651027 Review.
Cited by
-
Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.Cancer Chemother Pharmacol. 1993;31(4):269-76. doi: 10.1007/BF00685670. Cancer Chemother Pharmacol. 1993. PMID: 8422689